Division of Pulmonary, Critical Care, and Sleep Medicine, University of California San Diego, La Jolla, CA, USA.
Department of Cardio-Thoracic and Vascular Surgery, Heart and Lung Transplantation and Pulmonary Hypertension Unit, Foundation IRCCS Policlinico San Matteo, University of Pavia School of Medicine, Pavia, Italy.
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01294-2024. Print 2024 Oct.
Chronic thromboembolic pulmonary hypertension is a complication of pulmonary embolism and a treatable cause of pulmonary hypertension. The pathology is a unique combination of mechanical obstruction due to failure of clot resolution, and a variable degree of microvascular disease, that both contribute to pulmonary vascular resistance. Accordingly, multiple treatments have been developed to target the disease components. However, accurate diagnosis is often delayed. Evaluation includes high-quality imaging modalities, necessary for disease confirmation and for appropriate treatment planning. All patients with chronic thromboembolic pulmonary disease, and especially those with pulmonary hypertension, should be referred to expert centres for multidisciplinary team decision on treatment. The first decision remains assessment of operability, and the best improvement in symptoms and survival is achieved by the mechanical therapies, pulmonary endarterectomy and balloon pulmonary angioplasty. With the advances in multimodal therapies, excellent outcomes can be achieved with 3-year survival of >90%.
慢性血栓栓塞性肺动脉高压是肺栓塞的一种并发症,也是一种可治疗的肺动脉高压病因。其病理为血栓溶解失败引起的机械性阻塞与一定程度的微血管病变的独特组合,两者均导致肺血管阻力增加。因此,已经开发出多种治疗方法来针对疾病的各个方面。然而,准确的诊断往往会被延误。评估包括高质量的成像方式,这些方式对于疾病的确诊和适当的治疗计划是必要的。所有慢性血栓栓塞性肺疾病患者,尤其是那些患有肺动脉高压的患者,都应转至专家中心,由多学科团队决定治疗方案。首要决策仍然是评估可操作性,通过机械治疗(肺动脉内膜切除术和球囊肺动脉血管成形术)可获得症状和生存的最佳改善。随着多模式治疗的进步,采用这种治疗方法,患者 3 年生存率超过 90%,可获得良好的治疗效果。